Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
'Off-the-shelf'allogeneic CAR T cells: development and challenges
Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
F Marofi, HS Rahman, ZMJ Al-Obaidi, AT Jalil… - Stem Cell Research & …, 2021 - Springer
Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry - Nature reviews Clinical oncology, 2019 - nature.com
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer - Blood reviews, 2019 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
[HTML][HTML] Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Highlights•CAR T cells are associated with unique side-effects.•Cytokine release syndrome
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …
(CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and cytopenias are …
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …
How I treat cytopenias after CAR T-cell therapy
Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
Advances in universal CAR-T cell therapy
H Lin, J Cheng, W Mu, J Zhou, L Zhu - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …
results in antitumor treatments, especially against hematological malignancies, where it …